Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

GSK 1,464.50 +14.00 (0.97%)
price chart
GlaxoSmithKline Leads Borrowers Selling Most Debt Since March
May 2 (Bloomberg) -- GlaxoSmithKline Plc, the U.K.'s largest drugmaker, sold $5 billion of bonds in its first dollar-denominated offering in four years as companies market the most U.S.
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
Glaxo to Begin Hostile Offer for Human Genome Sciences
May 9 (Bloomberg) -- GlaxoSmithKline Plc will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S.
Glaxo's Melanoma Cocktail Slows Cancer in Study
May 17 (Bloomberg) -- GlaxoSmithKline Plc's combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single-drug ...
Dabrafenib And Trametinib: Melanoma Drug Combo Shows Promise In Small Trial  Huffington Post
Glaxo Scientist, Surgeon Targeting Historic British Hockey Gold
MacLeod, 27, also worked for GlaxoSmithKline Plc, the U.K.'s biggest drugmaker, as a sports scientist on its Lucozade energy drink.
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
May 25 (Bloomberg) -- GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.
Stock to Watch: Telecom Plus
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall.
GlaxoSmithKline: Complied With Indian Rules for Drug Approval
BANGALORE - GlaxoSmithKline GSK -0.49 % PLC said Thursday it was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs treating a ...
Indian Drug Regulator Accused of Corruption and Collusion  Bloomberg
Glaxo's Stiefel Unit Loses $1.5 Million Verdict on Buybacks
May 18 (Bloomberg) -- Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. Timothy Finnerty won the ...
GSK addresses Human Genome poison pill
by Laura Board | Published May 23, 2012 at 11:04 AM GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc. to address a poison pill mechanism its target put in place last week.
GlaxoSmithKline won't swallow Human Genome Sciences' poison pill  Washington Business Journal
GSK requests board to drop poison pill, blocking takeover of HGS  FinancialNews.co.uk